Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Woo Hyun Paik

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8708-3280; OpenAlex author ID A5080466465, A5137931949. Sources: OpenAlex.

Their work

Papers
36 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
80
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 5 papers · 2022: 5 papers · 2023: none · 2024: 6 papers · 2025: 2 papers · 2026: 5 papers

Papers 36

  1. Lorazepam and Survival in Asian Patients with Pancreatic Cancer: A Retrospective Cohort Study. Last author DOI 10.1007/s12029-026-01429-7↗
  2. Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial. Co-author DOI 10.1016/j.ejca.2026.116903↗
  3. Characteristics of Pancreatic Cancer-associated Ascites and Redefined Criteria for Bacterial Peritonitis. Co-author DOI 10.1097/mpa.0000000000002606↗
  4. Treatment Outcomes in Frail Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Real-World Comparison of Gemcitabine, S-1, and Stereotactic Ablative Rad… Last author DOI 10.1159/000552276↗
  5. Ferroptosis-based therapeutic strategy targeting iron metabolism and SLC7A11 overcomes oxaliplatin resistance in patient-derived pancreatic cancer organoids. Co-author DOI 10.1186/s13046-026-03745-z↗
  6. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  7. Metronidazole Exposure Has Limited Impact on Clinical Outcomes in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002499↗
  8. Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer. Co-author DOI 10.1002/jcsm.13437↗
  9. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.12049↗
  10. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. Co-author DOI 10.1016/j.adro.2023.101312↗
  11. Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16905↗
  12. Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib. Last author DOI 10.3390/cancers16051056↗
  13. Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. Co-author DOI 10.4062/biomolther.2023.109↗
  14. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Co-author DOI 10.1038/s43018-021-00326-1↗
  15. Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer: An Analysis Using Preclinical Adjuvant T… Co-author DOI 10.1097/mpa.0000000000002176↗
  16. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… Co-author DOI 10.1177/17588359221119539↗
  17. Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. Last author DOI 10.3389/fonc.2022.945829↗
  18. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. Co-author DOI 10.5009/gnl210166↗
  19. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, p… Co-author DOI 10.1177/17588359211056179↗
  20. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching … Co-author DOI 10.1186/s12885-021-08277-7↗
  21. Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Ca… Co-author DOI 10.3390/cancers13061196↗
  22. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Co-author DOI 10.5009/gnl19182↗
  23. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  24. Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2020.05.005↗
  25. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. Co-author DOI 10.5306/wjco.v11.i9.747↗
  26. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort. Co-author DOI 10.1002/cam4.2617↗
  27. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. Co-author DOI 10.1186/s12885-019-6193-0↗
  28. Comparison of Adjuvant Chemotherapy and Chemoradiation Therapy Efficacy for Pancreatic Cancer After R0 Resection: A Propensity Score-Matched Analysis Co-author DOI 10.21203/rs.2.12295/v1↗
  29. Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.12624↗
  30. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.5009/gnl18220↗
  31. The Author's Response: Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3346/jkms.2016.31.9.1505↗
  32. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3346/jkms.2015.30.7.917↗
  33. MicroRNA-200c as a Prognostic Biomarker for Pancreatic Cancer. Co-author DOI 10.4166/kjg.2015.66.4.215↗
  34. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i26.8545↗
  35. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 p… First author DOI 10.1371/journal.pone.0078977↗
  36. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Co-author PMID 23564788↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang Hyub Lee · 28 shared papers, 2013–2026 · strength 4.71
  2. Ji Kon Ryu · 28 shared papers, 2013–2026 · strength 4.53
  3. In Rae Cho · 14 shared papers, 2021–2026 · strength 3.16
  4. Yong‐Tae Kim · 21 shared papers, 2013–2025 · strength 2.80
  5. Jin Ho Choi · 14 shared papers, 2018–2026 · strength 2.47
  6. Wooil Kwon · 7 shared papers, 2019–2026 · strength 1.19
  7. Jin‐Young Jang · 6 shared papers, 2019–2024 · strength 0.88
  8. Jung Won Chun · 6 shared papers, 2019–2025 · strength 0.85
  9. Tae Seung Lee · 3 shared papers, 2024–2026 · strength 0.82
  10. Eui Kyu Chie · 4 shared papers, 2021–2026 · strength 0.81
  11. Min Su You · 6 shared papers, 2018–2021 · strength 0.64
  12. Ja‐Lok Ku · 3 shared papers, 2022–2026 · strength 0.60
  13. Gunn Huh · 5 shared papers, 2018–2021 · strength 0.58
  14. Hongbeom Kim · 3 shared papers, 2021–2024 · strength 0.45
  15. Min Woo Lee · 2 shared papers, 2024 · strength 0.43
  16. Woo Jin Lee · 2 shared papers, 2022–2025 · strength 0.35
  17. Sang Myung Woo · 2 shared papers, 2022–2025 · strength 0.35
  18. Tae Seung Lee · 1 shared paper, 2026 · strength 0.33
  19. J.H. Lee · 2 shared papers, 2022–2024 · strength 0.33
  20. Sang Kook Lee · 2 shared papers, 2022–2024 · strength 0.33
  21. Do‐Youn Oh · 2 shared papers, 2021–2024 · strength 0.32
  22. Jin‐Young Jang · 1 shared paper, 2026 · strength 0.32
  23. Dong Ho Lee · 1 shared paper, 2026 · strength 0.32
  24. Jae Young Lee · 1 shared paper, 2026 · strength 0.32
  25. Chang Hyun Kim · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.